Last reviewed · How we verify
NCT03410355: BMAC
Bone Marrow Aspirate Concentrate Use in Hip Osteoarthritis
NA trial testing BMAC/PRP Injection in Osteoarthritis, Hip in 6 participants. Terminated before completion.
17 May 2019
Quick facts
| Lead sponsor | Nova Scotia Health Authority |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 1 February 2018 |
| Primary completion | 17 May 2019 |
| Estimated completion | 17 May 2019 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- BMAC/PRP Injection
- Cortisone Injection — full drug profile →
Conditions studied
- Osteoarthritis, Hip — all drugs for Osteoarthritis, Hip →
Sponsor
Nova Scotia Health Authority — full company profile →
Who can join
Adults 16 to 60, any sex, with Osteoarthritis, Hip. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the effect of combined Bone marrow aspirate concentrate (BMAC) and Platelet Rich Plasma (PRP) action after a single hip intraarticular injection to young symptomatic patients with primary radiologic stage of hip OA (Kellgren-Lawrence grade I or II) compared to a control local anesthetic with cortisone injection group of patients. The hypothesis is that the patients with hip OA will benefit more and for longer from OA symptoms in the BMAC and PRP group rather than in the group of local anaesthetic and cortisone. Furthermore, this study could be valuable in determining the safety and effectiveness of the BMAC and PRP combined injection for early low grade hip OA in young active patients who are neither good candidates for total hip replacement nor preservative hip surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evolution and Innovations in Bone Marrow Cellular Therapy for Musculoskeletal Disorders: Tracing the Historical Trajectory and Contemporary Advances.
Lana JF, de Brito GC, Kruel A, Brito B, et al · · 2024 · cited 3× · PMID 39451354 · DOI 10.3390/bioengineering11100979
Verify or expand the search:
- PubMed search for NCT03410355
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Osteoarthritis, Hip
Currently open trials in the same condition.
- NCT07386561 — Virtual Reality Therapy and Non-Sleep Deep Rest Relaxation After Joint Arthroplasty · NA · active not recruiting
- NCT06578182 — The Effect of ColcHicine on the Incidence of Knee or Hip Replacements · Phase 3 · recruiting
- NCT06342843 — Direct Superior Approach Versus PosteroLateral Approach in Total Hip Arthroplasty (SPLAsH) · NA · recruiting
- NCT06249958 — Transforming Rehabilitation: Personalised Care for a Better Quality of Life · recruiting
- NCT05700682 — Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee · recruiting
Other Nova Scotia Health Authority trials
Trials by the same sponsor.
- NCT03716999 — Starlight Therapy in Palliative Care · not yet recruiting
- NCT06987409 — Continuous Erector Spinae Block for Analgesia Following Lumbar Decompression · NA · not yet recruiting
- NCT06575621 — Knee-hip Surgery Wait-list Support Program · NA · not yet recruiting
- NCT07143162 — YOGA-FIT: Protocol for a Crossover Trial Investigating the Feasibility and Impact of Yoga for People With Stroke · NA · not yet recruiting
- NCT07239999 — Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03410355 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nova Scotia Health Authority
- Last refreshed: 8 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03410355.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing